Who is sponsoring NCT01816074?

NCT01816074 is sponsored by Seattle Children's Hospital.

What drugs are being tested in NCT01816074?

Interventions in NCT01816074: Vyvanse (lisdexamphetamine), Behavior Parent Training.

What condition does NCT01816074 study?

NCT01816074 studies Attention Deficit Hyperactivity Disorder.

Is NCT01816074 still recruiting?

NCT01816074 is currently completed. Last updated 10 September 2018.

Are results published for NCT01816074?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-09-10 · How we verify

NCT01816074: TMF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children

Completed Phase 4 Results posted Last updated 10 September 2018

What this trial tests

Phase 4 trial testing Vyvanse (lisdexamphetamine) in Attention Deficit Hyperactivity Disorder in 53 participants. Completed in 1 May 2017.

Timeline

1 October 2012

Primary endpoint
1 October 2016

1 May 2017

Quick facts

Lead sponsor	Seattle Children's Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	53
Start date	1 October 2012
Primary completion	1 October 2016
Estimated completion	1 May 2017
Sites	1 location across United States

Drugs / interventions tested

Vyvanse (lisdexamphetamine) — full drug profile →
Behavior Parent Training

Conditions studied

Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

Seattle Children's Hospital

Who can join

Adults 21 to 50, female only, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Child Behavioral Functioning
Time frame: Baseline, Weeks 8 and 16
Child symptom severity will be assessed using the Clinical Global Impression - Severity (CGI-s) scale. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.

Sponsor's own description

We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may benefit most from multi-modal treatment

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
Chronis-Tuscano A, French W, Strickland J, Sasser T, et al · · 2020 · cited 3× · PMID 32926603 · DOI 10.4088/jcp.19m13173
Sequencing Stimulant Medication and Behavioral Parent Training in Multiplex ADHD Families: A Pilot SMART.
Lui JHL, Chronis-Tuscano A, Almirall D, Whitlock KB, et al · · 2025 · cited 2× · PMID 40009046 · DOI 10.4088/jcp.24m15463

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting

Other Seattle Children's Hospital trials

Trials by the same sponsor.

NCT07522112 — Evaluating a Shared Decision-making Intervention for Families About Firearm Storage · NA · not yet recruiting
NCT06864611 — Evaluating Huddles as a Novel Approach to Improving Concussion Safety · NA · not yet recruiting
NCT07424157 — Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products · not yet recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
NCT07097792 — Concussion Recovery and Support Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01816074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seattle Children's Hospital
Last refreshed: 10 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01816074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing